Ependymoma - Pipeline Review, H1 2017

Global Markets Direct
53 Pages - GMD17234
$2,000.00

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ependymoma – Pipeline Review, H1 2017, provides an overview of the Ependymoma (Oncology) pipeline landscape.

Ependymoma is a type of glioma that develops from ependymal cells. Ependymomas usually develop in the lining of the ventricles or in the spinal cord. The most common place they are found in children is near the cerebellum. The tumor often blocks the flow of the cerebral spinal fluid (CSF), causing increased intracranial pressure. Ependymomas are often slow growing tumours, and any signs and symptoms usually develop slowly over many months. The treatment for an ependymoma depends on a number of things, including your general health, the size and position of the tumour, and whether it has spread to other parts of the brain or spinal cord.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ependymoma – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ependymoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ependymoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ependymoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 2 and 3 respectively.

Ependymoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ependymoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ependymoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ependymoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ependymoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ependymoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ependymoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ependymoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

Advantagene Inc
Boehringer Ingelheim GmbH
Cavion LLC
Millennium Pharmaceuticals Inc
NewLink Genetics Corp

'

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ependymoma – Overview
Ependymoma – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Ependymoma – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ependymoma – Companies Involved in Therapeutics Development
Advantagene Inc
Boehringer Ingelheim GmbH
Cavion LLC
Millennium Pharmaceuticals Inc
NewLink Genetics Corp
Ependymoma – Drug Profiles
afatinib dimaleate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alisertib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GliAtak – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
indoximod – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mibefradil dihydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ependymoma – Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Ependymoma, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Ependymoma – Pipeline by Advantagene Inc, H1 2017
Ependymoma – Pipeline by Boehringer Ingelheim GmbH, H1 2017
Ependymoma – Pipeline by Cavion LLC, H1 2017
Ependymoma – Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Ependymoma – Pipeline by NewLink Genetics Corp, H1 2017
Ependymoma – Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Ependymoma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838